Fabrication of novel ruthenium loaded silk fibroin nanomaterials for fingolimod release improved antitumor efficacy in hepatocellular carcinoma

Dong Li,Chenmei Xia,Xia Chen,Qianqian Li,Jian Li,Xiaoqi Qian
DOI: https://doi.org/10.1080/09205063.2022.2090348
2022-07-13
Abstract:Cancer targeted nanomaterials-based drug delivery systems have been described as promising. In this work, we employed silk fibroin (SF), ruthenium nanomaterials (RuNMs), heptapeptide (T7), and fingolimod (FTY720) to construct a pH-responsive smart nanomaterials drug delivery system. They were spherical with a mean size of around 120 nm, which may have contributed to the improved penetration and retention of the NMs in tumour areas. T7-FTY720@SF-RuNMs had an encapsulation efficiency (EE) of 72.51 ± 4.02%. When the pH of an environment is acidic, the release of FTY720 from nanocarriers is enhanced. T7-FTY720@SF-RuNMs demonstrated increased cellular uptake selective and anticancer efficacy for hepatocellular cancer in both in vitro and in vivo experiments. Additionally, the in vivo biodistribution investigation showed that T7-FTY720@SF-RuNMs could efficiently aggregate in the tumour location, improving their in vivo potential to kill cancer cells. T7-FTY720@SF-RuNMs demonstrated little toxicity to tumour-bearing animals in investigations of histology and immunohistochemistry, showing that the fabricated NMs are biocompatible in vivo . For the treatment of hepatocellular cancer, the T7-FTY720@SF-RuNMs delivery method offers significant promise.
What problem does this paper attempt to address?